ReachMD CME

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-cultural-and-communication-disconnects-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37710/ In this case-based discussion, Dr. David Chin Yee presents his challenges and outcomes when managing a patient with diabetic macular edema who initially declined treatment due to language limitations, cultural beliefs, and mistrust of medical interventions. The case highlights the implementation of culturally sensitive strategies and underscores the value of cultural competence and patient-centered communication in overcoming barriers to care.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/patient-at-high-risk-of-loss-to-follow-up-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37711/ In this clinical discussion, Dr. Deepak Sambhara presents a case of a working-age man with severe non-proliferative diabetic retinopathy and diabetic macular edema. He details the diagnostic process using OCT and NIR imaging and explains how he engaged the patient in his treatment journey. Patient communication strategies are emphasized, as is a collaborative approach to address mistrust and enhance adherence. The case underscores the importance of individualized care and communication in retinal disease outcomes.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/a-case-of-missed-diagnosis-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37713/ In this case-based presentation, Dr. Esther Lee Kim reviews a young patient with long-standing type 2 diabetes who presented with bilateral vision loss and was initially referred for possible retinal vein occlusion. The case underscores how demographic factors can inform the risk of rapid disease progression, even in the setting of a relatively controlled HbA1c. Dr. Kim reviews longitudinal outcomes and offers clinical pearls emphasizing the importance of timely referral, frequent monitoring, and use of ancillary imaging to guide risk stratification and management in high-risk patients.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/it-takes-a-village-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37714/ In this didactic case presentation, Dr. David Eichenbaum discusses an 88-year-old patient with non-central geographic atrophy who received inappropriate bevacizumab treatment due to uncoordinated care after relocating seasonally. The case illustrates challenges that can arise in managing retinal disease across geographically distant sites. Dr. Eichenbaum emphasizes opportunities for improved referral handoffs, patient education, and system-based solutions to ensure continuity of evidence-based treatment.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/ This activity explores treatment sequencing strategies for chronic lymphocytic leukemia (CLL) following frontline therapy failure based on prior therapies, mechanisms of resistance, and minimal residual disease status. Dr. Jennifer Brown discusses how distinguishing between resistance and intolerance to BTK and BCL2 inhibitors informs second-line treatment decisions. The conversation highlights the role of measurable residual disease (MRD) in guiding therapy duration, biomarker reassessment, and shared decision-making based on patient preferences and clinical risk factors.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/ Dr. John Byrd discusses current and emerging strategies for managing double-class-refractory chronic lymphocytic leukemia (CLL) in community settings. He emphasizes the importance of distinguishing resistance from intolerance to BTK inhibitors through clinical history and molecular testing. Data from the BRUIN trial support the use of pirtobrutinib in select patients, while newer agents, including BTK degraders and bispecific antibodies, offer promising potential. Collaboration with CLL specialists is encouraged to guide therapy sequencing and access advanced treatments such as CAR T-cell therapy.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/ This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities, toxicities, IGHV status, and TP53 aberrations. They examine recent and emerging data from trials including CLL17, AMPLIFY, and BRUIN CLL-313, as well as novel agents. The conversation underscores the importance of personalized therapy selection in frontline CLL care.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/missing-the-window-in-ambulatory-patients-with-hfref-on-gdmt-strategies-for-cv-risk-reduction/48813/ For ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event, cardiologists continue to face a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support, these “stable,” guideline-treated patients carry residual risk for CV death. Recent evidence shows that the addition of soluble guanylate cyclase (sGC) stimulators provides significant reductions in CV death and all-cause mortality, particularly in individuals with moderately elevated NT-proBNP (≤6,000 pg/mL). However, cardiologists often underestimate risk in these ambulatory patients and may hesitate to add therapies when GDMT appears to be working well. Our experts break down a case to illustrate how and when to employ recent data regarding the use of additional sGC in appropriate patients with HFrEF.=

CME credits: 0.50 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/ This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanced and recurrent/metastatic disease. Faculty experts first explore new data on perioperative and adjuvant immunotherapy in locally advanced disease then discuss novel targeted and immunotherapy-based approaches that are showing promise in recurrent/metastatic disease. Safety profiles, patient-reported outcomes, and multidisciplinary considerations are addressed to support thoughtful integration of these therapies into real-world practice. These insights reinforce evolving strategies designed to enhance outcomes for patients across the full HNSCC spectrum.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/ This educational activity examines the growing evidence supporting bispecific antibodies in earlier treatment lines of multiple myeloma. Experts discuss the rationale for upstream use of bispecific antibodies and review key data from pivotal trials highlighting the evolving role for bispecific antibodies as early-line treatment. Practical considerations such as monitoring and managing adverse events associated with bispecific antibodies are discussed to guide real-world adoption. Together, these insights help clinicians integrate emerging evidence into practice to optimize patient outcomes as bispecific antibodies move earlier in the myeloma treatment paradigm. On March 5, 2026, the FDA approved teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/progress-in-breast-cancer-care-translating-sabcs-data-into-practice/48989/ This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participants will learn how to apply new evidence to expand therapeutic options, improve patient outcomes, and navigate emerging safety and quality of life considerations.=

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/unmet-need-second-line-outcomes-remain-poor-for-nsclc-and-pancreatic-cancer/54118/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanistic-evolution-in-ras-therapy-on-state-and-multi-selective-targeting/54120/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

CME credits: 0.75 Valid until: 28-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/ This video series focuses on translating multimodality imaging into practical care for patients with hypertrophic cardiomyopathy (HCM). Expert faculty review echocardiography, cardiac magnetic resonance, and emerging imaging strategies to support diagnosis, guide HCM-specific therapies, including the use of cardiac myosin inhibitors, and monitor treatment response. Case-based discussions highlight imaging patterns that inform prognosis and optimize patient outcomes.=

CME credits: 0.25 Valid until: 27-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/Frontline-Insights-Emerging-Therapeutic-Strategies-in-HNSCC/49223/ This online educational activity highlights cutting-edge clinical trial data shaping the future of care in both locally advanced and recurrent/metastatic HNSCC. Experts review novel approaches such as perioperative immunotherapy, radioenhancers in the definitive setting, and next-generation targeted therapies including bispecific antibodies in advanced disease. Faculty compare toxicity profiles across these strategies, emphasizing practical approaches to early adverse event recognition, prevention, and management. With a focus on real-world implementation, the program equips clinicians to translate investigational findings into informed treatment decisions and safer patient care. =

CME credits: 0.25 Valid until: 23-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-line-moving-bispecific-antibodies-upstream-in-treating-multiple-myeloma/49265/ This expert lecture offers a focused review of the expanding role of bispecific antibodies earlier in the disease course of multiple myeloma. Learn about pivotal trial data with unprecedented efficacy that support this shift to use in early-line settings. Safety considerations, including infection risk and mitigation strategies, are addressed to guide real-world implementation. Together, these insights help clinicians optimize patient outcomes as bispecific antibodies move toward earlier integration in multiple myeloma care. On March 5, 2026, the FDA approved teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.=

CME credits: 1.00 Valid until: 15-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/interdisciplinary-strategies-for-brca-mutated-ebc-testing-targeting-and-team-based-care/36606/ This online educational activity, derived from a live Grand Rounds event, focuses on the application of molecular testing, evidence-based therapy selection, and interdisciplinary collaboration in the management of high-risk early-stage breast cancer (EBC) with germline BRCA mutations. In this chapterized activity, Dr. Jane Meisel reviews practical approaches for implementing guideline-directed BRCA testing and highlights disparities that impact equitable access to precision oncology. She also discusses the latest clinical evidence on adjuvant therapy for patients with high-risk EBC with germline BRCA mutations and uses a case-based learning lab to explore individualized adjuvant treatment strategies for these patients. The program also emphasizes proactive management of treatment-related adverse events, including patient counseling and coordinated supportive care, to optimize safety and adherence. Participants will gain practical strategies for integrating germline BRCA mutational status into treatment planning and for strengthening multidisciplinary care pathways, all in service of improving outcomes and reducing disparities for patients with high-risk EBC.=

CME credits: 1.00 Valid until: 06-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/oh-the-hats-youll-wear-the-many-modalities-of-pediatric-obesity-management/39966/ On-demand webcast of expert faculty presentation on the diagnosis and management of obesity for pediatric patients, including communication and patient-centered care strategies to improve health outcomes.=

CME credits: 1.00 Valid until: 05-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/spotlight-on-systemic-sclerosis-pathophysiology-presentation-emerging-evidence/48716/ Systemic sclerosis (SSc) is complex and often diagnosed late. Explore the vasculopathy-fibrosis axis as a key driver of disease progression and clinical manifestations. Learn to recognize phenotypic red flags for ILD, PAH, and renal crisis, and apply risk stratification strategies to guide earlier intervention. Check out the evolving evidence on treatment selection and serious complications, emphasizing multidisciplinary care models and the role of patient-reported outcomes.=

CME credits: 1.00 Valid until: 05-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/ Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bring these concepts to life, with special attention to application in VA and academic settings. Whether you're a medical oncologist, ocular oncologist, ophthalmologist, or APP, this discussion is designed to sharpen your skills and your care aligned with the latest science. =

CME credits: 1.00 Valid until: 02-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/asparaginase-based-treatment-young-adults-all/37193/ Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult protocols for young adults with ALL. However, many patients continue to be treated with adult protocols that lack asparaginase and are associated with poorer outcomes. In this dynamic, case-based activity, celebrity advocates Rob Benedict and Abbie Cobb, leading leukemia experts, and real people who have been treated for ALL explore practical foundations for successful asparaginase therapy. Leveraging new consensus recommendations, faculty experts explain how to select and when to switch asparaginase formulations, how to monitor serum asparaginase activity, and strategies to mitigate key toxicities while avoiding early asparaginase discontinuation that can compromise survival. Real-world stories from young adults who have been treated for ALL highlight the stakes of getting this right and the challenges of access, adherence, and comprehensive care that clinicians can address in everyday practice. Learning Goal/Purpose The goal of this educational activity is to enhance the knowledge, competence, and confidence that hematology/oncology healthcare providers need to achieve better outcomes for young adults with ALL through more consistent application of pediatric-inspired regimens, optimized …=

CME credits: 0.25 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-and-diagnosis-logistics-navigating-complexity-across-ages/39028/ Drs. Jonathan Strober and Diana Castro examine the diagnostic approach to generalized myasthenia gravis (gMG), with a focus on age-related differences in clinical presentation. They describe early signs in pediatric patients—such as ptosis and impaired extraocular movements—and contrast these with the fluctuating fatigue, bulbar involvement, and proximal muscle weakness more commonly seen in adults. The discussion includes practical strategies for diagnostic confirmation and highlights the role of antibody testing and the limitations of electrophysiologic studies in children. The faculty emphasize the importance of keeping MG in the differential diagnosis to minimize delays in recognition and treatment.=

CME credits: 0.25 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/gmg-patient-stratification-and-antibody-profiling-personalizing-the-disease-lens/39029/ This discussion between Drs. Diana Castro and Jonathan Strober focuses on the clinical utility of patient stratification and antibody profiling in generalized myasthenia gravis (gMG). The conversation addresses how age of onset, antibody status (acetylcholine receptor, MuSK, LRP4), and comorbidities can influence diagnosis and management plans. The speakers highlight the limitations of current pediatric assessment tools and the implications of antibody status for access to targeted therapies. Practical considerations for repeat testing, use of modified clinical scales, and individualized communication strategies with pediatric patients and families are also examined, emphasizing the nuanced approach required in younger populations.=

CME credits: 0.25 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/mg-therapeutic-selection-and-monitoring-efficacy-matching-mechanisms-to-patients/39030/ Drs. Diana Castro and Jonathan Strober discuss treatment strategies for generalized myasthenia gravis (gMG), focusing on pediatric and adolescent care. They review traditional therapies and newer agents, such as FcRn and complement inhibitors, highlighting the role of antibody status and considerations for thymectomy. The conversation also addresses monitoring challenges, including limitations of clinical scales and the importance of patient and caregiver input in assessing treatment response.=

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/severity-assessment-can-you-pin-the-stage-on-the-patient/51481/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-treatment-can-you-select-the-best-therapy/51483/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/treat-to-target-are-we-there-yet/51485/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/remission-can-you-prove-it/51486/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/switching-strategies-switch-or-staywhats-your-call/51487/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 0.25 Valid until: 30-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/earlier-action-lasting-impact-closing-the-ldl-c-gap-in-patients-without-a-prior-mace/39957/ This program explores evolving strategies for low-density lipoprotein cholesterol (LDL-C) management in patients at high cardiovascular (CV) risk who have not yet experienced a myocardial infarction or stroke. Drs. Bohula and Leiter discuss unmet needs, shifting LDL-C targets, and emerging treatment strategies, including PCSK9 inhibitors and results from the VESALIUS-CV trial. The conversation highlights how early, intensive LDL reduction can meaningfully lower the risk of first CV events. Practical guidance is shared on risk assessment, statin optimization, evaluating and managing statin intolerance, and the use of combination lipid-lowering therapy.=

CME credits: 1.00 Valid until: 16-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/primary-care-for-the-brain-prevention-and-early-detection-of-cognitive-decline/39897/ In this on-demand webcast, leading experts in brain health provide guidance for patient education, discussion, and management geared toward HCPs in primary care who are at the forefront of an aging population at risk of cognitive decline trying to plan for its future and for whom brain health is a topic of uttermost importance.=

CME credits: 0.25 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/ This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic therapy in this new guidance. Despite broad endorsement, many clinicians remain uncertain about applying the new framework. This activity aims to raise awareness, clarify updated criteria, and align practice with current evidence supporting earlier use of IL-23 and IL-17 inhibitors in appropriate patients.=